Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) in clinical classification of Pulmonary Hypertension Group1~* The mean right heart catheterization parameters measured from 6 months prior to the administration of the investigational drug must meet the criteria below:~* Mean pulmonary arterial pressure (mPAP) of \>25 mmHg~* Pulmonary vascular resistance (PVR) of \>3 mmHg/L/min~* Mean pulmonary capillary wedge pressure or left ventricular end diastolic pressure of \<15 mmHg (if measurable)~* The measured six minutes walk distance (6MWD) at screening visit is in the range of =\>150m and \<=450m

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1325760A (Type: EXPERIMENTAL): Single arm safety and efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).